Janux Q3 2025 net loss narrows to $24.3M; cash at $989M; trial enrollment continues

Janux Therapeutics, Inc.

2025-Q3 EPS reported -$1.32 revenue$10,000,000

Net loss of $24.3M improved from $28.1M in Q3 2024; R&D expense rose to $34.6M from $18.6M.
Cash, equivalents & short-term investments totaled $989.0M, down from $1.03B at Dec 31, 2024.
Enrollment ongoing in Phase 1 trials for JANX007 (mCRPC) and JANX008 (solid tumors); data updates expected Q4 2025.
G&A expense fell to $10.6M vs $17.7M, last year included $9.5M stock-comp modification charge.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.